tive product portfolio, so that we can continue for at
market,” says Borges.
alties have always been in the areas of respiratory,
nd inflammation. However, the productive strategy
repared Zambon to be able to partner with new
ensing. “We are seeking acquisitions in Brazil, for both
cts, and we are seeking opportunities to partner with
e product licensing with. Over the next two years,
he current size of the company, through business
artnerships,” says Borges.
September 2012
Medications
page 483
com
